

Harnessing the Power of T Cells to Tackle Solid Tumors

The EUREKA THERAPEUTICS® approach to fighting solid tumors such as liver cancer is to develop multiple potential treatment options for patients by cultivating a deeper understanding of your specific type of cancer and leveraging our cutting-edge technology platforms, E-ALPHA® and ARTEMIS®.




E-ALPHA®

Discovery platform for developing highly specific antibodies



ARTEMIS®

Utilizing the natural biology of T cells to fight cancer



Electron Microscope image of an ET140203 T cell (blue) attacking a liver cancer cell (red).

Eureka's U.S. Phase I/II Clinical Trials for Adult and Pediatric Patients with Liver Cancer

ET140203 T Cells

Target: AFP peptide/HLA-A2 complex

ARYA-1

Age Group:	Adult
Liver Cancer Type(s):	• HCC
Target Population:	Failed at least 2 different anti-HCC systemic agents
ClinicalTrials.gov Identifier:	NCT04502082
Active Sites:	• Kansas University Medical Center • City of Hope

ARYA-2

Age Group:	Pediatric
Liver Cancer Type(s):	• HCC • HB • HCN-NOS
Target Population:	Relapsed/Refractory disease
ClinicalTrials.gov Identifier:	NCT04634357
Active Sites:	• Dana-Farber Cancer Institute

ECT204 T Cells

Target: GPC3

ARYA-3

Age Group:	Adult
Liver Cancer Type(s):	• HCC
Target Population:	Failed at least 2 different anti-HCC systemic agents
ClinicalTrials.gov Identifier:	NCT04864054
Active Sites:	• Kansas University Medical Center • City of Hope

For more information about our therapies and U.S. clinical trials, visit our website at:

www.eurekaconnectme.com